Lenacapavir: Two Shots. $40. Everywhere.

Tell Gilead: Drop the price of long-acting PrEP!

A game-changer in HIV prevention is now here: lenacapavir (LEN), an injection which only needs to be given twice a year and is nearly 100 percent effective in preventing HIV.

However, Gilead, the drug company that manufactures LEN, is keeping it out of reach for many people in low- and middle-income countries (LMICs). Gilead sells LEN at very high prices (over $28,000 per person per year in the US), severely restricts its supply to certain countries, and refuses to sell it directly to Doctors Without Borders/Médecins Sans Frontières (MSF).

A medical breakthrough like LEN should be available everywhere. Now.

For Pride, we're demanding HIV prevention for all

We marched at Pride for more than celebration. We're demanding that a groundbreaking new HIV prevention medicine be available for everyone.

MSF provides health care and advocates for access to treatment and prevention for people living with and affected by HIV. MSF provides pre-exposure prophylaxis (PrEP), like LEN, to communities in LMICs facing heightened risk of HIV, including men who have sex with men, transgender people, sex workers, people who inject drugs, and incarcerated people, as well as those in conflict and other fragile humanitarian contexts.

We are calling on Gilead to:

Reduce the price of LEN to less than $40 per person per year in all LMICs
Increase its global supply to match actual demand
Sell LEN directly to MSF and others

HIV isn’t waiting – why is Gilead?

Join our campaign

Sign up here to join our campaign! We will add your name to our call for global access to this HIV prevention breakthrough, and send you campaign updates and more info on what we’re doing.

News update

Campaign update

September 17, 2026 — Thanks in part to campaign pressure, Gilead announced a "pathway" for access to generic lenacapavir in excluded Latin American countries, but crucial details like price and supply remain unknown.

Campaign brief: Two shots. $40. Everywhere.

Campaign factsheet: Two Shots. $40. Everywhere

Campaign social media toolkit

Get the toolkit

Technical brief: Gilead’s voluntary license on lenacapavir

MSF at AIDS 2026

Gilead, governments must make lenacapavir more accessible

HIV prevention should not be a privilege

MSF International President Dr. Javid Abdelmoneim explains that a drug exists that is nearly 100 percent effective at preventing HIV and only needs to be taken twice a year. It's called lenacapavir.

More on lenacapavir

September 17 03:07 PM

Pharma monopoly limits impact of new PAHO deal for HIV prevention drug

Efforts to create a regional pathway for lenacapavir are welcome, but Gilead’s continued control over pricing and supply means that the drug will remain out of reach for most in Latin America and the Caribbean.

MSF joins activists to march at the International AIDS Conference in Rio de Janeiro to demand that Gilead make lenacapavir, a groundbreaking HIV prevention tool, accessible to everyone.

September 08 08:00 AM

Why Dr. Noc is joining forces with MSF to call for access to HIV medicine

Scientist and influencer Dr. Morgan McSweeney, PhD, also known as @dr.noc, explains why the HIV prevention medicine lenacapavir is so vital — and why it must be made accessible to everyone who needs it.

August 04 12:23 PM

AIDS 2026 ends without Gilead increasing access to lenacapavir

Gilead offered no concrete plan to ensure people in Latin America can access its game-changing HIV prevention medicine.

July 23 09:58 AM

AIDS 2026: Gilead, governments must make HIV prevention medicine more accessible

Brazil has hosted clinical trials paving the way for lenacapavir’s approval and sale, but the medicine remains widely inaccessible for people there.

MSF USA staff marched at NYC Pride on June 28, calling on Gilead Sciences to make lenacapavir more accessible.

June 24 10:20 AM

MSF at Pride: Gilead must increase global access to HIV prevention medicine

HIV isn’t waiting – why is Gilead?

MSF staff hold a Love Without Borders sign at a Pride march in Belgium.

June 17 09:20 AM

Game-changing HIV prevention drug must be available for $40 per year — everywhere

Gilead must do more to ensure enough lenacapavir is available worldwide to turn the tide on the HIV/AIDS pandemic.

Sameer*, a patient living with advanced HIV, talks to a counselor at the Guru Gobind Singh Hospital in Patna, Bihar.

April 30 03:31 PM

Gilead stockholders: Demand Gilead sell HIV prevention drug to those who need it

The pharmaceutical corporation must do more to ensure people have access to lenacapavir worldwide.

Meena Kumari, lay counsellor, in a conversation with a caregiver of a person living with HIV. Guru Gobind Singh Hospital in Patna, Bihar.

April 30 07:19 AM

Gilead won’t sell MSF its HIV drug. Its shareholders should ask why

The company’s refusal to sell lenacapavir to MSF is a failure that will be measured by the number of people who acquire HIV despite possible prevention.

Dr Tandzile Nhlengetfwa walks through the waiting area in the Sitsandziwe Clinic, Eswatini

April 14 01:02 PM

Gilead is not doing enough to expand access to groundbreaking HIV prevention medicine

The company’s limited supply of lenacapavir is a tiny fraction of what's needed to confront the HIV epidemic.

Satish*, an advanced HIV survivor talks to a doctor in India.

March 30 08:59 AM

Gilead refuses to sell groundbreaking HIV prevention drug to MSF

Blocking humanitarian organizations from accessing a medical breakthrough puts vulnerable people across the world in danger.

MSF Dr. Dilorom Babakhodjaeva provides consultations for people with HIV, hepatitis C, and syphilis in Tashkent, Uzbekistan.

March 30 12:29 AM

Open letter to Gilead: Prevention should not be a privilege

MSF calls on Gilead for direct access to lenacapavir, as the current rollout falls far short of the needs.

Protesters at the International AIDS Conference call for for a price reduction for CAB-LA and LEN-LA.

September 26, 2025

MSF supports $40 PrEP access by 2027, demands broader reach and more ambition to end HIV epidemic

Lenacapavir: Two Shots. $40. Everywhere.